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a  b  s  t  r  a  c  t
Ethnopharmacological  relevance:  Morus  nigra,  commonly  known  as  black  mulberry,  is widely  used  in
Brazilian  folk  medicine  for the  diabetes  treatment.
Aim of this  study:  To  evaluate  the  effect  of  Morus  nigra  aqueous  extract  treatment  on  maternal  lipid
and  oxidative  stress  proﬁle,  reproductive  outcomes,  and  also  fetal  anomaly  incidence  from  diabetic  and
non-diabetic  rats.
Materials and  methods:  Diabetes  was  induced  by streptozotocin  (40  mg/kg)  in virgin  female  Wistar  rats.
Morus  nigra  leaf  aqueous  extract  (400  mg/kg)  was  administered  from  day  0  to  20  of  pregnancy.  At  day  21
of pregnancy,  all rats  were  anesthetized  and  killed  to  obtain  blood  samples  and  maternal–fetal  data.
Results  and  conclusion:  After  treatment  with  Morus  nigra  extract,  non-diabetic  and  diabetic  rats  presented
no  glycemic  changes.  Fetuses  from  diabetic  dams,  regardless  of  Morus  nigra treatment,  were  small foreproductive outcome
nomaly
pregnancy  age.  In diabetic  dams,  plant  treatment  caused  reduced  MDA,  cholesterol,  triglycerides  and
VLDL  levels,  and  decreased  placental  index  and  weight  as compared  to  diabetic  group.  The  fetuses  from
diabetic  rats  treated  with  Morus  nigra  extract  had  lower  frequency  of  skeletal  and  visceral  anomalies  as
compared to diabetic  group.  Thus,  Morus  nigra  leaf  aqueous  extract  failed  to control  hyperglycemia  in
diabetic  rats. However,  Morus  nigra treatment  had  antioxidant  effect,  contributing  to reduce  incidence
of  internal  anomalies  in  offspring  from  diabetic  dams.
 . Introduction
Diabetes mellitus is a group of metabolic diseases character-
zed by hyperglycemia resulting from defects in insulin secretion
nd/or action, or both. Several pathogenic processes are involved
n diabetes development (Reece et al., 2004; American Diabetes
ssociation, 2011). In pregnancies complicated by diabetes, hyper-
lycemia and lipid metabolism alterations are associated with both
aternal and fetal complications (Merzouk et al., 2000; HAPO Study
ooperative Research Group, 2008). Excessive oxidative stress has
een implicated in the pathology and complications of diabetic
regnancy (Zhao and Reece, 2005). During pregnancy, diabetes
eads to reproductive abnormalities that enhance spontaneous
bortion, congenital anomalies, and neonatal morbidity and mor-
ality (Van Assche et al., 1998; Eriksson et al., 2003). The rates of
pontaneous abortion are three times more common in diabetes
nd pregnancy association. Despite advances in obstetric care and
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diabetes management, the risks for morbidity and mortality are
increased for the human with diabetes and their offspring (Diabetes
and Pregnancy Group, 2003; Dunne et al., 2003).
Several drugs are used to control diabetes, however perfect
glycemic control is rarely achieved (Cooppan, 2005). From ancient
times, plants have been used for treatment of Diabetes mellitus
(Volpato et al., 2002; Damasceno and Volpato, 2008). The use of
medicinal plants as alternative therapy is widely spread in the pop-
ulations of underdeveloped countries, which have limited access
to medical assistance. Diabetic women often use aqueous extracts
of plants during pregnancy without any concern as to their pos-
sible outcomes. The effects of many of these plants have already
been proven experimentally in animals and humans while others
require further investigations (Prince et al., 1998).
The use of medicinal plants such as Morus nigra L. (family:
Moraceae), known as black mulberry, and other members of its
genus can be found in many countries. However, almost all the
parts of the tree are used for pharmacological actions all over the
world (Singab et al., 2005; Pawlowska et al., 2008). Its berries, bark
Open access under the Elsevier OA license.and leaves are used medicinally, the berries for inﬂammation and to
stop bleeding, the bark for toothache, and the leaves for snakebites
and as an antidote to action poisoning. In Europe, black mulberry
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reatment (Ody Mnimh, 2000; Naderi et al., 2004). The hypo-
lycemic effect of the black mulberry leaves is similar to the anti-
iabetic activity of glibenclamide in patients with type 2 diabetes
Andallu et al., 2001). Experimental studies have also demonstrated
he hypoglycemic effect of black mulberry extract (Hosseinzadeh
nd Sadeghi, 1999; Michinori et al., 2001; Petlevski et al., 2001).
revious study in our laboratory demonstrated that Morus nigra
eaf extract did not present toxicological and hypoglycemic effects
n diabetic and non-diabetic pregnant rats (Volpato et al., 2005).
Oxidative reaction has also been implicated by low density
ipoprotein (LDL) oxidation in atherosclerosis (Rakesh et al., 1999).
here are many reports concerning the structural changes of bio-
ogical membranes induced by active oxygen species (Naderi et al.,
004). Black mulberry contains soluble plant chemicals known as
ioﬂavonoids. These powerful antioxidants may  be responsible for
heir medicinal properties (Ursell, 2000; González et al., 2010).
herefore, it is important to study Morus nigra effect in oxidative
tress and lipid proﬁle of experimental diabetic pregnancy.
Several diabetic pregnant women that arrived for medical inves-
igation in the Botucatu Medical School, São Paulo, Brazil, report
he use of medicinal plants, such as black mulberry leaves, to treat
iabetes because of the high cost of the antidiabetic drug. Thus, the
bjective of the present study was to investigate the oral treatment
ffects with Morus nigra leaf aqueous extract on maternal repro-
uctive outcomes, lipid and oxidative stress proﬁle, and also fetal
nomaly incidence from the streptozotocin-induced diabetic and
on-diabetic rats.
. Materials and methods
.1. Extraction of plant materials
The leaves of Morus nigra were collected from Botucatu, São
aulo State, Brazil, between January and May  2007, in the morning.
he plant was identiﬁed and authenticated by experts from Botani-
al Department (Unesp – Botucatu, São Paulo State, Brazil), where a
oucher specimen (BOTU 25412) has been deposited. The leaves of
he plant were dried at 50 ◦C for a period of 24 h in an aerated stove,
round and a powder was prepared, similarly to the folk-medicine
reparation method. Morus nigra aqueous extract was  prepared by
oiling 50 g of the powder of the leaves of the plant in a ﬂask con-
aining 1 L of water for 5 min. The extract was agitated and covered
ntil it reached room temperature. The residue was removed by ﬁl-
ration and the extract was  then suitably concentrated in a rotary
vaporator (ﬁnal concentration: 50 mg/mL). A sample was sepa-
ated for determination of the solid concentration, and the extract
as divided into aliquots stored at −20 ◦C until further use.
.2. Experimental animals
Female and male Wistar rats (190–210 g) were obtained from
nesp – Botucatu Breeding Center, and were maintained under
tandard laboratory conditions (22 ± 3 ◦C, 12-h light/dark cycle),
ith pelleted food (Purina rat chow, Purina®, São Paulo, SP, Brazil)
nd tap water ad libitum.  The animals were cared for in accordance
ith the principles of the Guide for Care and Use of Experimental
nimals. The local Committee of Ethics in Animal Experimenta-
ion approved all experimental procedures of this study (Protocol
umber 545/2004).
After two weeks of acclimatization, diabetes was induced in
emale rats with streptozotocin (STZ, Sigma Chemical Company,
t. Louis, Millstone) (Froede and Medeiros, 2008). STZ was  admin-
stered (i.v.) in a dose of 40 mg/kg dissolved in citrate buffer (0.1 M,
H 6.5). Control rats received (i.v.) citrate buffer. Blood glucose con-
entrations were measured by One Touch Ultra Johnson & Johnson®rmacology 138 (2011) 691– 696
glucometer 7 days after induction of diabetes, and concentrations
exceeded 200 mg/dL conﬁrmed the diabetic state (Volpato et al.,
2009).
2.3. Experimental groups
After diabetic state was conﬁrmed, virgin female Wistar rats
were mated overnight with non-diabetic male Wistar rats. The
morning on which sperm were found in the vaginal smear was
designated gestational day 0 (Francia-Farje et al., 2010). This study
was composed of four experimental groups (n minimum = 13 ani-
mals/group): non-diabetic; non-diabetic treated with Morus nigra
extract; diabetic and diabetic treated with Morus nigra extract. The
treatment dose of 400 mg/kg/day of the Morus nigra extract was
orally given, by gavage, from day 0 until the day 20 of pregnancy.
2.4. Course of pregnancy
Glycemia was  measured about every seven days up to the end
of pregnancy, at approximately 9 a.m. At day 21 of pregnancy,
the rats were anesthetized by sodium pentobarbital and blood
samples were collected by decapitation for biochemical parame-
ters. The gravid uterus was  weighed and dissected to count dead
and live fetuses, resorption, implantation, and corpora lutea num-
bers. The number of implantation sites was  determined by the
Salewski method (1964).  The fetuses and placentas were weighed
to calculate the placental index as: placental weight/fetal weight.
The male/female percentage ratio was calculated. The mean birth
weight of the control pups (G1) was 5.4 ± 0.4 g. Newborns in the
experimental groups whose birth weights did not diverge more
than ±1.0 standard deviation (SD) from the G1 mean (i.e., those
that were within the 5.0–5.8-g range) were classiﬁed as adequate
for pregnancy age (APA). Those whose weights were at least 1.0
SD greater than the G1 mean birth weight were classiﬁed as large
for pregnancy age (LPA). Those whose birth weights were at least
1.0 SD lower than the G1 mean birth weight were classiﬁed as
small for pregnancy age (SPA) (Volpato et al., 2008), and evalu-
ated in a microscope with respect to incidence of external anomaly.
After external analysis, half the fetuses were ﬁxed in Bouin’s ﬂuid
and serial sections were prepared as described by Wilson (1965)
for visceral examination. The remaining fetuses were prepared for
examination of the skeletons by the staining procedure of Staples
and Schnell (1964).
2.5. Biochemical proﬁle analysis
One part of blood samples was  collected from each rat and so
put into anticoagulant-free test tubes, maintained at ice for 30 min
and then centrifuged at 1300 × g during 10 min  at 4 ◦C. The super-
natant was  collected as serum and stored at −80 ◦C for further
determination of biochemical parameters.
Serum concentrations of total cholesterol (CHO), triglycerides
(TG) and high-density lipoprotein (HDL) were determined by using
the enzymatic method; and total protein (TP) concentrations were
estimated by colorimetric method (Young, 2000), all of them by
Sigma assay kits. The values were expressed in milligrams (mg)
per deciliter (dL). Very-low-density lipoprotein (VLDL) serum level
estimated value was calculated through the triglyceride concentra-
tions (Friedwald et al., 1972).
For oxidative stress analysis, another blood portion was  put into
anticoagulant tubes, and then centrifuged at 90 × g for 10 min  at
25 ◦C. Plasma content was discarded and so erythrocyte contents
were washed using phosphate-saline buffer followed by centrifu-
gation at 1300 × g during 1 min  at 4 ◦C. This procedure was  done for
three times for assay of oxidative stress biomarkers, as described by
de Souza et al. (2010).  Oxidative stress biomarkers measured were
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Table 1
Biochemical proﬁle of non-diabetic and diabetic rats treated or not with a Morus nigra aqueous extract during pregnancy.
Groups
Non-diabetic Non-diabetic treated Diabetic Diabetic treated
TP (g/dL) 7.02 ± 2.14 6.88 ± 3.54 7.06 ± 2.87 3.56 ± 1.76
CHO  (mg/dL) 119.15 ± 18.70 112.88 ± 29.06 349.23 ± 286.96* 137.99 ± 40.91#
TG (mg/dL) 352.46 ± 112.90 503.00 ± 261.91 1186.98 ± 652.55* 545.44 ± 349.87#
HDL (mg/dL) 33.51 ± 20.43 53.45 ± 21.38 41.26 ± 17.76 45.14 ± 15.38
VLDL  (mg/dL) 67.55 ± 24.35 143.27 ± 114.54 237.40 ± 130.51* 109.09 ± 69.97#
MDA  (nM/g Hb) 49.85 ± 10.24 108.82 ± 70.73 685.84 ± 789.36* 46.74 ± 29.68#



























rata shown as mean ± standard deviation (SD).
* p < 0.05 compared to non-diabetic group (Bonferroni test).
# p < 0.05 compared to diabetic group (Bonferroni test).
uperoxide dismutase activity (SOD) and malonaldehyde (MDA) as
ipid peroxidation index.
.6. Statistical evaluation
The Kruskal–Wallis test, followed by Dunn’s test, was  used for
omparison between experimental groups as regards the num-
er of implantations, live fetuses, resorptions and fetal weight. For
lycemia, biochemical parameters, number of corpora lutea, gravid
terine weight, and maternal weight gain was applied Analysis of
ariance (ANOVA), followed by Bonferroni test. The percentual val-
es were calculated by the Fisher Exact Test (Zar, 2009). Differences
ere considered statistically signiﬁcant when p < 0.05.
. Results
As shown in Fig. 1, non-diabetic group presented a glycemic
evel under 100 mg/dL. Blood glucose levels were higher than
00 mg/dL in the diabetic pregnant rats. The treatment with Morus
igra aqueous extract did not interfere with glycemias from non-
iabetic or diabetic groups compared to respective untreated
roups (Fig. 1).
Table 1 shows the proﬁle evaluation of biochemical parameters
f all experimental groups studied. There were not any signiﬁcant
ifferences for total protein and HDL-lipoprotein levels and GSH-
x activity among different groups. The non-diabetic rats treated
ith the plant extract presented increased SOD activity. Diabetic
tatus was observed in this study by increased CHO, TG and VLDL-
ipoprotein levels as compared to non-diabetic group. The diabetic
ig. 1. Glycemia on days 0, 7, 14 and 21 of non-diabetic and diabetic rats treated
r  not with a Morus nigra aqueous extract during the pregnancy. Data shown as
ean ± standard deviation (SD). *p < 0.05 compared to non-diabetic group (Bonfer-
oni test).rats treated with Morus nigra had signiﬁcantly reduced MDA,  CHO,
TG and VLDL serum concentrations.
There were no changes in the parameters of the reproduc-
tive outcome in the non-diabetic group treated with plant extract
compared to non-diabetic group. The diabetic group, regardless
of Morus nigra treatment, presented increase in placental index,
placental weight, percentage of resorption per implantation sites,
and SPA fetuses; reduced percentage of live fetuses per implan-
tation sites, maternal weight gain, maternal weight gain free of
gravid uterus, fetal body weight, and percentage of APA and LPA
fetuses as compared to non-diabetic group. Corpora lutea and live
fetus numbers, and gravid uterus weight in the diabetic dams were
signiﬁcantly lower than those of non-diabetic group. Morus nigra
treatment in diabetic group reduced placental index and weight
compared to diabetic group (Table 2).
There were no signiﬁcant differences among the four exper-
imental groups with respect to frequency of external anomaly.
Similarly, there were no signiﬁcant differences in frequencies of
skeletal and visceral anomalies in non-diabetic group treated with
the plant extract as compared to non-diabetic group. The diabetic
groups (untreated and treated) presented signiﬁcant decrease in
ossiﬁcation centrum and increase in number and percentage of
fetus per litter with skeletal anomalies (dumbbell ossiﬁcation of
vertebral centrum, supernumerary rib, sternebra agenesis, incom-
plete ossiﬁcation of sternebra, and abnormally shaped sternebra)
and total number of fetuses with visceral alteration as compared
to non-diabetic group. The diabetic group also presented high per-
centage of fetus with visceral anomalies per litter (microphthalmia,
hydroureter, and hydronephrosis) as compared to non-diabetic
rats. The fetuses from diabetic dams exposed to Morus nigra extract
had smaller incidence of skeletal anomalies, such as cleft palate,
bipartite ossiﬁcation of vertebral centrum, supernumerary rib,
sternebra agenesis, incomplete ossiﬁcation of sternebra, and abnor-
mally shaped sternebra compared to diabetic group. The treatment
with the plant extract in diabetic rats also decreased the num-
ber and percentage of fetus per litter with visceral anomalies, and
incidence of fetal microphthalmia and hydroureter compared to
diabetic group (Table 3).
4. Discussion and conclusions
The importance of use of medicinal plants is being widely
experimentally studied at about 40 years all over the world, and
the information used about the plant effects is collected and
very knowledged by the folk reports. Besides, Morus nigra is also
included, its leaves have been shown to possess diuretic, hypo-
glycemic, and hypotensive activities, whereas the root bark of
mulberry trees has long been used for antiinﬂammatory, antitus-
sive, and antipyretic properties (Pawlowska et al., 2008).
Diabetic patients have used Morus nigra extract for the treat-
ment of diabetes, and diabetic women  often use aqueous extracts
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Table 2
Reproductive outcome from non-diabetic and diabetic rats treated or not with a Morus nigra aqueous extract during the pregnancy.
Groups
Non-diabetic Non-diabetic treated Diabetic Diabetic treated
Pregnant females (N) 17 20 18 14
Pregnant at term (N) 17 20 15 12
With  total resorptions (N) 0 0 3 2
Corpora lutea
Total (N) 239 267 215 167
Mean  ± SD 14.06 ± 1.68 13.35 ± 1.53 11.94 ± 1.98* 12.50 ± 1.91
Implantationa
Total (N) 210 251 201 161
Mean  ± SD 12.35 ± 2.37 12.55 ± 2.42 11.17 ± 1.58 11.50 ± 2.31
Live  fetusesa
Total (N) 199 242 145 131
Mean ± SD 11.71 ± 2.34 12.10 ± 2.40 9.06 ± 3.34* 10.92 ± 2.68
Per  implantation sites (%) 94.76 96.00 72.14* 81.37*
Dead  fetusesa
Total (N) 2 0 2 1
Mean  ± SD 0.12 ± 0.33 0.10 ± 0.31 0.13 ± 0.34 0.08 ± 0.29
Resorptionsa
Total (N) 9 7 54 29
Mean  ± SD 5.16 ± 5.75 3.26 ± 6.23 22.63 ± 57.13 6.81 ± 11.76
Per  implantation sites (%) 4.29 2.78 26.87* 18.01*
Sex  ratio (M/F)b 80/95 120/122 58/75 72/59
Maternal weight gain (g) 134.00 ± 22.17 138.35 ± 21.22 64.67 ± 44.96* 77.21 ± 45.57*
Gravid  uterus weight (g) 82.62 ± 15.39 84.21 ± 16.44 65.96 ± 17.65* 70.37 ± 17.67
Maternal weight gain minus gravid uterus weight (g) 49.08 ± 17.27 54.14 ± 14.69 15.31 ± 15.74* 19.38 ± 23.88*
Fetal  body weight (g)a
Mean ± SD 5.40 ± 0.38 5.38 ± 0.42 4.44 ± 0.71* 4.73 ± 0.62*
SPA  Fetuses (%)b 23.5 27.4 77.8* 79.4*
APA  fetuses (%)b 47.3 53.5 17.7* 15.6*
LPA  fetuses (%)b 29.2 20.1 4.5* 5.0*
Placental weight (g)
Mean ± SD 0.47 ± 0.05 0.46 ± 0.05 0.66 ± 0.28* 0.52 ± 0.05*,#
Placental index (g)































i, number. Data shown as mean ± standard deviation (SD) and proportions (%).
* p < 0.05 compared to non-diabetic group (Bonferroni; aKruskal–Wallis test; bFis
# p < 0.05 compared to diabetic group (Bonferroni; aKruskal–Wallis test; bFisher E
f plants during pregnancy, including Morus species, without any
oncern as to their possible repercussions. In the present study,
orus nigra treatment led no antihyperglycemic effect in diabetic
ams and caused no hypoglycemic action in non-diabetic pregnant
ats. These data did not support folk reports, but they conﬁrmed
revious results found in our laboratory (Volpato et al., 2005). This
ight be justiﬁed due to administered dose, short treatment period,
resence of uncontrolled diabetes and the difference of sensitivity
mong the plants used and the animals tested, which would pre-
ent the effective action by the plant extract. Contradictorily, there
as evidence that Morus nigra extract (Hosseinzadeh and Sadeghi,
999; Mudra et al., 2007) and other species of Morus (Andallu et al.,
001; Singab et al., 2005; Naowaboot et al., 2009) present hypo-
lycemic effects.
Our data showed that Morus nigra extract caused reduction in
holesterol, triglycerides and VLDL levels in diabetic dams, decreas-
ng to similar concentrations as compared to non-diabetic rats.
osta et al. (2007) also veriﬁed that Croton cajucara presented
ypolipidemic effect in rats due to presence of terpenoids. Morus
igra has signiﬁcant ﬂavonoid concentrations (Pawlowska et al.,
008) and, similar to terpenoids, ﬂavonoids possess also hypolipi-
emic action (Jung et al., 2006).
In this study, the diabetic dams presented exacerbated lipoper-
xidation as conﬁrmed by increased MDA  level. Many reports have
een published that support the use of antioxidant supplemen-
ation at reducing oxidative stress and at slowing or preventing
he development of diabetic complication in animals (Kaul et al.,
995; Keegan et al., 1995). The non-diabetic rats treated with plant
xtract in our study presented increased level of enzymatic antiox-
dant activity (SOD), showing Morus nigra presented antioxidantact Test).
est).
effect. In diabetic state, the aqueous extract treatment decreased
levels of MDA, suggesting increased SOD consumption led to nor-
mal  MDA  rates. Naderi et al. (2004) also showed antioxidant effect
of Morus nigra treatment in vitro. There are several vegetal com-
pounds that may  inﬂuence the up-regulation about antioxidant
proﬁle, like betulinic acid (Zheng et al., 2011). This substance was
already identiﬁed by HPLC in leaf extracts of Morus nigra, showed
in Padilha et al.’s (2010) study. Besides betulic acid, these authors
also identiﬁed germanicol and -sitosterol, members of the class
of triterpenes and steroids.
In diabetic group, there was  decrease in corpora lutea and
live fetuses, and consequently, a decreased gravid uterus weight.
The treatment with Morus nigra prevented these complications.
In women with uncontrolled diabetes, miscarriages are frequent
(Eriksson et al., 2003). The diabetic state caused higher frequency
of embryonic deaths leading to increased number of resorptions
and decreased percentage of live fetuses per implantation sites.
Morus nigra treatment did not prevent the development of these
complications in the diabetic rats and did not interfere with these
parameters in non-diabetic rats. There were higher rates of small
fetuses for pregnancy age, corroborating with experimental studies
performed in our laboratory, which showed that rats with severe
diabetes also presented a fetuses with intrauterine growth restric-
tion (Rudge et al., 2007; Volpato et al., 2008; Damasceno et al.,
2011). Maternal hyperglycemia causes fetal hyperglycemia, which
contributes for fetal hypoinsulinemia. The decreased fetal insu-
linemia has also been suggested in the etiology of fetal growth
restriction. If insulin is decreased in the fetuses from diabetic
mother, hypoinsulinemia causes fetal growth restriction seen in
diabetic pregnancy (Holemans et al., 2003). In our study, the
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Table 3
Frequency of fetal anomalies from non-diabetic and diabetic rats treated or not with a Morus nigra aqueous extract during the pregnancy.
Variables Groups
Non-diabetic Non-diabetic treated Diabetic Diabetic treated
External anomalies
Number fetuses examined (litter) 201 (17) 243 (20) 117 (12) 132 (12)
Total number of fetuses (%) with alteration 0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)
Mean  % fetuses with alteration per litter (mean ± SD) 0.0 ± 0.0 0.0 ± 0.0 1.1 ± 0.6 0.0 ± 0.0
Gastrosquises 0  (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)
Exencephaly 0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)
Skeletal anomalies
Number fetuses examined (litter) 105 (17) 71 (12) 60 (12) 67 (12)
Mean of total number of ossiﬁcation centrum (mean ± SD) 38.0 ± 3.3 39.3 ± 4.8 28.9 ± 6.0a 32.2 ± 3.2a
Total number of fetuses (%) with alteration 38 (36.2%) 25 (35.2%) 47 (78.3%)* 46 (68.7%)*
Mean  % fetuses with alteration per litter (mean ± SD) 35.5 ± 22.7 37.4 ± 28.3 82.7 ± 33.3a 70.7 ± 25.8a
Incomplete ossiﬁcation of cranius 0 (0.0%) 0 (0.0%) 2 (3.4%) 1 (1.5%)
Cleft  palate 1 (0.9%) 0 (0.0%) 17 (28.3%)* 0 (0.0%)#
Dumbbell ossif. of vertebral centrum 2 (1.9%) 0 (0.0%) 15 (25.0%)* 11 (16.4%)*
Bipartite ossif. of vertebral centrum 2 (1.9%) 2 (2.8%) 13 (28.3%)* 1 (1.5%)#
Supranumerary rib 17 (16.2%) 13 (18.3%) 38 (63.3%)* 30 (44.8%)*,#
Wavy rib 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.0%)
Sternebra agenesis 2 (1.9%) 1 (1.4%) 17 (28.3%)* 7 (10.4%)*,#
Unossiﬁed sternebra 3 (2.8%) 1 (1.4%) 3 (5.0%) 1 (1.5%)
Incomplete ossiﬁcation of sternebra 13 (12.4%) 10 (14.0%) 28 (46.7%)* 18 (26.9%)*,#
Extra ossiﬁcation site of sternebra 0 (0.0%) 0 (0.0%) 1 (1.7%) 0 (0.0%)
Abnormally shaped sternebra 7 (6.7%) 10 (14.0%) 48 (80.0%)* 32 (47.8%)*,#
Visceral anomalies
Number fetuses examined (litter) 93 (17) 112 (19) 57 (12) 65 (12)
Total number of fetuses (%) with alteration 16 (17.2%) 13 (11.6%) 31 (54.4%)* 23 (35.4%)*,#
Mean % fetuses with alteration per litter (mean ± SD) 17.1 ± 21.1 11.3 ± 16.7 57.4 ± 26.0a 36.7 ± 21.3
Microphthalmia 1 (1.0%) 0 (0.0%) 6 (10.5%)* 2 (3.1%)#
Ectopic kidney 2 (2.1%) 6 (5.4%) 2 (3.5%) 10 (15.4%)*,#
Dilated renal pelvis 7 (7.2%) 5 (4.5%) 6 (10.5%) 11 (16.9%)
Hydroureter 5 (5.2%) 2 (1.8%) 10 (17.5%)* 1 (1.5%)#































c* p < 0.05 compared to non-diabetic group (Fisher Exact Test).
# p < 0.05 compared to diabetic group (Fisher Exact Test).
a p < 0.05 compared to non-diabetic group (Kruskal–Wallis test).
lacental weight and index were greater in the diabetic rats. How-
ver, this increased placental weight was insufﬁcient for fetal
ourishment. As a result, there was a higher proportion of small
or pregnancy age fetuses in the diabetic groups, thus conﬁrming
he existence of placental dysfunction in maternal–placental–fetal
xchanges (Calderon et al., 1992). Morus nigra extract was not able
o increase the rates of fetuses classiﬁed as APA and LPA in the
iabetic group.
Hyperglycemia during embryogenesis has been associated with
irth defects in pregnancies complicated by diabetes (Damasceno
t al., 2002). The anomalies most often affect the central ner-
ous system, heart and large vessels, kidneys, and axial skeleton
Schaefer-Graf et al., 2000). In our investigation, Morus nigra treat-
ent in non-diabetic group did not alter the incidence of external,
keletal, and visceral anomalies compared to non-diabetic group.
n the same way, the treatment of Morus nigra did not alter the
ncidence of external anomaly in diabetic group. The diabetes
aused increase in skeletal and visceral anomalies. The most
ommon skeletal anomalies in fetuses were cleaf palate, dumbbell
nd bipartite ossiﬁcation of vertebral centrum, supernumerary rib,
nd in sternebra (agenesis, incomplete ossiﬁcation, and abnor-
ally shaped). About the visceral anomalies, the diabetic group
resented high incidence of microphthalmia, hydroureter, and
ydronephrosis. The treatment of Morus nigra presented signiﬁ-
ant decrease in rate of these anomalies in diabetic group. There
as also decreased total number of fetuses with visceral alteration
nd percentage of fetuses with alteration per litter. Nevertheless,
aternal glicemic control was not the mechanism by which
orus nigra treatment reduced the rates of these anomalies. This
act could be related to the presence of substances present in this
xtract, which might act in response to an increased oxidative stress
aused by diabetes. Support for this hypothesis comes mainly fromevidence that antioxidant enzymes provide protection against free
radical-induced malformations (Reece and Eriksson, 2004). It was
shown in our laboratory that Bauhinia forfocata extract, containing
exogenous antioxidant, signiﬁcantly reduced the anomaly rate in
offspring from diabetic rats (Volpato et al., 2008).
The assessment of the ossiﬁcation sites of the fetuses, proposed
by Aliverti et al. (1979),  is important in determining the fetal stage
of maturity at birth. Diabetes resulted in delayed skeletal develop-
ment as evidenced by the smaller number of ossiﬁcation centrum
in fetuses compared to fetuses from non-diabetic groups. Chahoud
and Paumgartten (2005) veriﬁed strongest correlation between
body weight and degree of ossiﬁcation. These retarded ossiﬁcation
and the lower fetal body weight indicated that diabetes caused pre-
natal growth retardation and impaired fetal somatic development,
and the Morus nigra treatment did not alter these ﬁndings.
In conclusion, Morus nigra leaf aqueous extract was  not toxic at
the dose level used in this study, but it failed to control the maternal
hyperglycemia, pregnancy rate, and placental–fetal development
in diabetic rats. However, Morus nigra treatment had antioxidant
effect contributing to reduce incidence of skeletal and visceral
anomalies in offspring from diabetic dams. The effects of medic-
inal plants and other co-adjuvant resources, which may affect
antioxidant status during the course of experimental diabetes in
pregnancy, as an approach to devising inexpensive therapeutic
measures for the management of the many and varied disturbances
of embryofetal development of clinical diabetes.
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